Current medical treatments result in survival of some longer than 10 years; in part this is because better diagnostic testing means early diagnosis and treatments. Older diagnosis and treatments resulted in published reports of median survival of approximately 5 years from time of diagnosis. Currently, median survival is 6.5 years. In rare instances,<unk>  progresses to multiple myeloma. The International Prognostic Scoring System for<unk> 's<unk>  is a predictive model to characterise long-term outcomes. According to the model, factors predicting reduced survival are: * Age > 65 years * Hemoglobin ≤ 11.5 g/dL * Platelet count ≤ 100×109/L * B2-microglobulin > 3 mg/L * Serum monoclonal protein concentration > 70 g/L The risk categories are: * Low: ≤ 1 adverse variable except age * Intermediate: 2 adverse characteristics or age > 65 years * High: > 2 adverse characteristics Five-year survival rates for these categories are 87%, 68% and 36%, respectively. The corresponding median survival rates are 12, 8, and 3.5 years. The International Prognostic Scoring System for<unk> 's<unk>  has been shown to be reliable. It is also applicable to patients on a rituximab-based treatment regimen. An additional predictive factor is elevated serum lactate dehydrogenase (LDH).
Waldenström macroglobulinemia
Monoclonal gammopathy of undetermined significance
AL amyloidosis
Fibrin-associated diffuse large B-cell lymphoma
POEMS syndrome
Thymoma with immunodeficiency
Multiple myeloma
Diffuse large B-cell lymphoma